M. Ishida

发表

Characteristics and risk factors of acute dystonia in schizophrenic patients treated with nemonapride, a selective dopamine antagonist.

K. Otani, S. Kaneko, T. Kondo, 1999, Journal of clinical psychopharmacology.

Increases in plasma concentration of m-chlorophenylpiperazine, but not trazodone, with low-dose haloperidol.

K. Otani, A. Suzuki, S. Kaneko, 1997, Therapeutic drug monitoring.

The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients.

T. Kondo, K. Otani, A. Suzuki, 2001, Pharmacogenetics.

Possible interaction between cisapride and bromperidol

K. Otani, S. Kaneko, M. Ishida, 1997, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Plasma concentrations of trazodonb and m-chlorophenylpiperazine at steady state can be predicted from those after an initial dose of trazodone

K. Otani, S. Kaneko, T. Kondo, 1997, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Effects of various factors on steady state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine.

K. Otani, S. Kaneko, H. Higuchi, 1995, International clinical psychopharmacology.

Prolactin response to zotepine in schizophrenic patients

K. Otani, H. Higuchi, S. Kaneko, 1993 .

Increased plasma concentrations of bromperidol and its reduced metabolite with levomepromazine, but not with thioridazine.

K. Otani, A. Suzuki, S. Kaneko, 1997, Therapeutic drug monitoring.

No interaction between desipramine and bromperidol

K. Otani, A. Suzuki, S. Kaneko, 1996, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Adverse Effects of Zotepine and Their Relationship To Serum Concentrations of the Drug and Prolactin

K. Otani, S. Kaneko, T. Kondo, 1994, Therapeutic drug monitoring.

Plasma prolactin concentration and psychopathology of schizophrenia

K. Otani, A. Suzuki, S. Kaneko, 1996, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

High‐performance Liquid Chromatographic Determination of Trazodone and 1‐m‐Chlorophenylpiperazine with Ultraviolet and Electrochemical Detector

N. Yasui, K. Sugawara, T. Ohkubo, 1995, The Journal of pharmacy and pharmacology.

Associations between side effects of nemonapride and plasma concentrations of the drug and prolactin

S. Kaneko, T. Kondo, N. Tokinaga, 2002, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Relationship Between Plasma Concentrations of Trazodone and Its Active Metabolite, m-Chlorophenylpiperazine, and Its Clinical Effect in Depressed Patients

K. Otani, S. Kaneko, T. Kondo, 2002, Therapeutic drug monitoring.

Is 2‐Propyl‐4‐Pentenoic Acid, a Hepatotoxic Metabolite of Valproate, Responsible for Valproate‐Induced Hyperammonemia?

K. Otani, S. Kaneko, H. Kudo, 1992, Epilepsia.

No pharmacokinetic but pharmacodynamic interactions between cisapride and bromperidol or haloperidol.

K. Otani, A. Suzuki, S. Kaneko, 1999, Therapeutic drug monitoring.

Associations Between Risk Factors for Valproate Hepatotoxicity and Altered Valproate Metabolism

K. Otani, S. Kaneko, T. Hirano, 1992, Epilepsia.

The characteristics of side‐effects of bromperidol in schizophrenic patients

K. Otani, S. Kaneko, T. Kondo, 2002, Psychiatry and clinical neurosciences.

Effects of Various CYP2D6 Genotypes on the Steady-State Plasma Concentrations of Risperidone and Its Active Metabolite, 9-Hydroxyrisperidone, in Japanese Patients With Schizophrenia

T. Iga, N. Yasui-Furukori, Y. Takarada, 2003, Therapeutic drug monitoring.

Effects of zonisamide on extracellular levels of monoamine and its metabolite, and on Ca2+ ependent dopamine release

M. Okada, T. Hirano, T. Kondo, 1992, Epilepsy Research.

Therapeutic effects of bromperidol on the five dimensions of schizophrenic symptoms

K. Otani, A. Suzuki, S. Kaneko, 2002, Progress in Neuro-psychopharmacology and Biological Psychiatry.

Prolactin response to bromperidol treatment in schizophrenic patients.

K. Otani, A. Suzuki, S. Kaneko, 1998, Pharmacology & toxicology.

Interaction between carbamazepine and bromperidol

K. Otani, A. Suzuki, S. Kaneko, 1997, European Journal of Clinical Pharmacology.

Effects of carbamazepine coadministration on plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine.

K. Otani, S. Kaneko, K. Sugawara, 1996, Therapeutic drug monitoring.

Inhibition of Trazodone Metabolism by Thioridazine in Humans

K. Otani, S. Kaneko, T. Kondo, 1995, Therapeutic drug monitoring.

No effect of the anticholinergic drugs trihexyphenidyl and biperiden on the plasma concentrations of bromperidol and its reduced metabolite.

K. Otani, A. Suzuki, S. Kaneko, 1997, Therapeutic drug monitoring.

Mechanisms of the development of trazodone withdrawal symptoms.

K. Otani, S. Kaneko, O. Tanaka, 1994, International clinical psychopharmacology.

A study of the therapeutic spectrum of a fixed‐dose of zotepine and its relationship with serum concentrations of the drug

K. Otani, S. Kaneko, T. Kondo, 1993 .

Hyperglycemia as a symptom of neuroleptic malignant syndrome

K. Otani, M. Ishida, S. Kaneko, 1996 .

Correlation between prolactin response and therapeutic effects of zotepine in schizophrenic patients

K. Otani, S. Kaneko, T. Kondo, 1994, International clinical psychopharmacology.

Trazodone treatment increases plasma prolactin concentrations in depressed patients

K. Otani, S. Kaneko, N. Yasui, 1995, International clinical psychopharmacology.